Phase II
The Right to Try Act, signed into law by President Donald Trump last spring, may be seeing its first fruits. A California brain cancer patient who did not qualify for participation in a clinical trial will get the chance to see if an experimental glioblastoma treatment will save his life.
Moderna’s clinical and business update at the JP Morgan Healthcare Conference led the newly public company shares to pop 4.2 percent, a welcome change.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
In an interview with CNBC Monday, Novartis Chief Executive Officer Vas Narasimhan noted that the company is looking to become an entity that doesn’t draw its profits from treating disease, but will make money by providing cures.
Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US
Karolinska Development’s portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD).
Galapagos NV expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with ‘1690 in IPF.
Biotech entrepreneur Vivek Ramaswamy has launched another subsidiary for Roivant Sciences. Ramaswamy will provide an update on the new company, as well as other members of the Roivant family during a Monday presentation at JPM19.
DTX401 Response Observed in All Three Patients, with Two Patients Demonstrating Clinically Meaningful Improvement in Time to Hypoglycemia
ADOCIA announced today the first home-use trial to test Adocia’s BioChaperone® Lispro in Beta Bionics autonomous insulin delivery system, the iLetTM.
PRESS RELEASES